Solvay sells pharma operations to Abbott for $6.6B Print E-mail
By Staff and Wire Reports   
Monday, 28 September 2009 05:48

Sale likely to be completed in the first quarter of 2010, pending antitrust approval from the EU and U.S. Abbott wanted Solvay as a way to expand into emerging markets in Eastern Europe and Asia, reports stated.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter